Patents by Inventor Mark Munson

Mark Munson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Arylamides and methods of use thereof
    Patent number: 12637414
    Abstract: The present disclosure relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.
    Type: Grant
    Filed: June 3, 2022
    Date of Patent: May 26, 2026
    Assignee: Genzyme Corporation
    Inventors: Junkai Liao, Mark Munson, Zhongli Gao, Gregory Hurlbut, Hans Peter Nestler, Ingrid Mechin, Joseph Kim, Martin Smrcina, Nina Ma, Ronghua Li, Ryan Hartung, William Bock, Bertrand Vivet
  • Arylamides and methods of use thereof
    Patent number: 12630498
    Abstract: The present disclosure relates to substituted aryl amide compounds, according to Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.
    Type: Grant
    Filed: June 3, 2022
    Date of Patent: May 19, 2026
    Assignee: Genzyme Corporation
    Inventors: Junkai Liao, Mark Munson, Zhongli Gao, Gregory Hurlbut, Hans Peter Nestler, Helen Yeoman, Martin Smrcina, Ronghua Li, Ryan Hartung, William Wire, Bertrand Vivet, Nina Ma, William Bock, Aleksandra Weichsel, Andrew Scholte
  • Arylamides and methods of use thereof
    Patent number: 12630521
    Abstract: The present disclosure relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.
    Type: Grant
    Filed: June 3, 2022
    Date of Patent: May 19, 2026
    Assignee: Genzyme Corporation
    Inventors: Junkai Liao, Mark Munson, Zhongli Gao, Gregory Hurlbut, Hans Peter Nestler, Ingrid Mechin, Martin Smrcina, Ronghua Li, Ryan Hartung, William Bock, Bertrand Vivet, Andrew Scholte
  • Macrocyclic compounds, compositions, and methods of using thereof
    Patent number: 12624051
    Abstract: The present disclosure includes, among other things, CFTR modulators, pharmaceutical compositions, and methods of making and using the same.
    Type: Grant
    Filed: September 12, 2025
    Date of Patent: May 12, 2026
    Assignees: Genzyme Corporation, Sionna Therapeutics Inc.
    Inventors: Junkai Liao, John E. Macor, George Topalov, Mark Munson, Sukanthini Thurairatnam, Bradford Hirth, Zhongli Gao, Gregory Donald Hurlbut, Andrew Good, Roy Vaz, Jinyu Liu, Yi Li, Anatoly Ruvinsky, Michael Kothe, David Borcherding, Patrick Bernardelli, Arielle Genevois Borella, Franck Caussanel, Ingrid Devillers, Eric Nicolai, Franck Slowinski, Fabienne Thompson, Lothar Schwink, Heiner Glombik, Stefan Guessregen, Michael Podeschwa, Nils Rackelmann, Sven Ruf
  • 6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficient CFTR activity
    Patent number: 12583824
    Abstract: The invention relates to heteroaryl compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.
    Type: Grant
    Filed: May 11, 2022
    Date of Patent: March 24, 2026
    Assignee: Genzyme Corporation
    Inventors: Zhongli Gao, Gregory Hurlbut, Mark Munson, Junkai Liao
  • MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF
    Publication number: 20260008786
    Abstract: The present disclosure includes, among other things, CFTR modulators, pharmaceutical compositions, and methods of making and using the same.
    Type: Application
    Filed: September 12, 2025
    Publication date: January 8, 2026
    Inventors: Junkai Liao, John E. Macor, George Topalov, Mark Munson, Sukanthini Thurairatnam, Bradford Hirth, Zhongli Gao, Gregory Donald Hurlbut, Andrew Good, Roy Vaz, Jinyu Liu, Yi Li, Anatoly Ruvinsky, Michael Kothe, David Borcherding, Patrick Bernardelli, Arielle Genevois Borella, Franck Caussanel, Ingrid Devillers, Eric Nicolai, Franck Slowinski, Fabienne Thompson, Lothar Schwink, Heiner Glombik, Stefan Guessregen, Michael Podeschwa, Nils Rackelmann, Sven Ruf
  • MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF
    Publication number: 20260008785
    Abstract: The present disclosure includes, among other things, CFTR modulators, pharmaceutical compositions, and methods of making and using the same.
    Type: Application
    Filed: September 12, 2025
    Publication date: January 8, 2026
    Inventors: Junkai Liao, John E. Macor, George Topalov, Mark Munson, Sukanthini Thurairatnam, Bradford Hirth, Zhongli Gao, Gregory Donald Hurlbut, Andrew Good, Roy Vaz, Jinyu Liu, Yi Li, Anatoly Ruvinsky, Michael Kothe, David Borcherding, Patrick Bernardelli, Arielle Genevois Borella, Franck Caussanel, Ingrid Devillers, Eric Nicolai, Franck Slowinski, Fabienne Thompson, Lothar Schwink, Heiner Glombik, Stefan Guessregen, Michael Podeschwa, Nils Rackelmann, Sven Ruf
  • COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF
    Publication number: 20250326749
    Abstract: The present disclosure relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.
    Type: Application
    Filed: June 9, 2023
    Publication date: October 23, 2025
    Inventors: Junkai Liao, Mark Munson, Zhongli Gao, Gregory Hurlbut, John E. Macor
  • MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF
    Publication number: 20250248975
    Abstract: The present disclosure includes, among other things, CFTR modulators, pharmaceutical compositions, and methods of making and using the same.
    Type: Application
    Filed: March 5, 2025
    Publication date: August 7, 2025
    Inventors: Junkai Liao, John E. Macor, George Topalov, Mark Munson, Sukanthini Thurairatnam, Bradford Hirth, Zhongli Gao, Gregory Donald Hurlbut, Andrew Good, Roy Vaz, Jinyu Liu, Yi Li, Anatoly Ruvinsky, Michael Kothe, David Borcherding, Patrick Bernardelli, Arielle Genevois Borella, Franck Caussanel, Ingrid Devillers, Eric Nicolai, Franck Slowinski, Fabienne Thompson, Lothar Schwink, Heiner Glombik, Stefan Guessregen, Michael Podeschwa, Nils Rackelmann, Sven Ruf
  • MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF
    Publication number: 20250197422
    Abstract: The present disclosure includes, among other things, CFTR modulators, pharmaceutical compositions, and methods of making and using the same.
    Type: Application
    Filed: March 5, 2025
    Publication date: June 19, 2025
    Inventors: Junkai Liao, John E. Macor, George Topalov, Mark Munson, Sukanthini Thurairatnam, Bradford Hirth, Zhongli Gao, Gregory Donald Hurlbut, Andrew Good, Roy Vaz, Jinyu Liu, Yi Li, Anatoly Ruvinsky, Michael Kothe, David Borcherding, Patrick Bernardelli, Arielle Genevois Borella, Franck Caussanel, Ingrid Devillers, Eric Nicolai, Franck Slowinski, Fabienne Thompson, Lothar Schwink, Heiner Glombik, Stefan Guessregen, Michael Podeschwa, Nils Rackelmann, Sven Ruf
  • MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF
    Publication number: 20250197420
    Abstract: The present disclosure includes, among other things, CFTR modulators, pharmaceutical compositions, and methods of making and using the same.
    Type: Application
    Filed: March 5, 2025
    Publication date: June 19, 2025
    Inventors: Junkai Liao, John E. Macor, George Topalov, Mark Munson, Sukanthini Thurairatnam, Bradford Hirth, Zhongli Gao, Gregory Donald Hurlbut, Andrew Good, Roy Vaz, Jinyu Liu, Yi Li, Anatoly Ruvinsky, Michael Kothe, David Borcherding, Lothar Schwink, Heiner Glombik, Stefan Guessregen, Michael Podeschwa, Nils Rackelmann, Sven Ruf
  • INDOLE COMPOUNDS AND METHODS OF USE
    Publication number: 20240279220
    Abstract: The invention relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.
    Type: Application
    Filed: March 1, 2024
    Publication date: August 22, 2024
    Inventors: Junkai Liao, Mark Munson, Sukanthini Thurairatnam, Bradford Hirth, Zhongli Gao, Gregory Hurlbut, David Borcherding, Matthieu Barrague, Timothy Alan Gillespy, Alexandre Gross, Andrew Good, Roy Vaz, Jinyu Liu, Yi Li, Markus Metz, Anatoly Ruvinsky, Claude Barberis
  • INDOLE COMPOUNDS AND METHODS OF USE
    Publication number: 20240239784
    Abstract: The invention relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.
    Type: Application
    Filed: March 1, 2024
    Publication date: July 18, 2024
    Inventors: Junkai Liao, Mark Munson, Sukanthini Thurairatnam, Bradford Hirth, Zhongli Gao, Gregory Hurlbut, David Borcherding, Matthieu Barrague, Timothy Alan Gillespy, Alexandre Gross, Thaddeus Nieduzak, Andrew Good, Roy Vaz, Jinyu Liu, Yi Li, Markus Metz, Anatoly Ruvinsky, Michael Kothe
  • 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY
    Publication number: 20240002374
    Abstract: The invention relates to heteroaryl compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.
    Type: Application
    Filed: May 11, 2022
    Publication date: January 4, 2024
    Inventors: Junkai Liao, Mark Munson, Zhongli Gao, Gregory Hurlbut, Sylvie Baltzer, Bertrand Vivet, Brian Freed, Hans Peter Nestler, Helen Yeoman, Ingrid Mechin, Martin Smrcina, Nina Ma, Sylvain Lebreton, Ryan Hartung, William Wire, Sukanthini Thurairatnam
  • CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE
    Publication number: 20230348450
    Abstract: Provided herein are compounds and compositions thereof for modulating bis-phosphoglycerate mutase (BPGM) for treating sickle cell disease.
    Type: Application
    Filed: September 14, 2021
    Publication date: November 2, 2023
    Inventors: Kunal Desai, Zhong Fang, Kevin Guertin, Vu Hong, John Ziqi Jiang, Sungtaek Lim, Mark Munson
  • COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE
    Publication number: 20230348454
    Abstract: Provided herein are compounds and compositions thereof for modulating bis-phosphoglycerate mutase (BPGM) for treating sickle cell disease.
    Type: Application
    Filed: September 14, 2021
    Publication date: November 2, 2023
    Inventors: Kunal Desai, Zhong Fang, Kevin Guertin, Vu Hong, John Ziqi Jiang, Sungtaek Lim, Jinyu Liu, Mark Munson
  • ARYLAMIDES AND METHODS OF USE THEREOF
    Publication number: 20230159439
    Abstract: The present disclosure relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.
    Type: Application
    Filed: June 3, 2022
    Publication date: May 25, 2023
    Inventors: Junkai Liao, Mark Munson, Zhongli Gao, Gregory Hurlbut, Hans Peter Nestler, Ingrid Mechin, Joseph Kim, Martin Smrcina, Nina Ma, Ronghua Li, Ryan Hartung, William Bock, Bertrand Vivet
  • ARYLAMIDES AND METHODS OF USE THEREOF
    Publication number: 20230159438
    Abstract: The present disclosure relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.
    Type: Application
    Filed: June 3, 2022
    Publication date: May 25, 2023
    Inventors: Junkai Liao, Mark Munson, Zhongli Gao, Gregory Hurlbut, Hans Peter Nestler, Helen Yeoman, Martin Smrcina, Ronghua Li, Ryan Hartung, William Wire, Bertrand Vivet, Nina Ma
  • ARYLAMIDES AND METHODS OF USE THEREOF
    Publication number: 20230147360
    Abstract: The present disclosure relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.
    Type: Application
    Filed: June 3, 2022
    Publication date: May 11, 2023
    Inventors: Junkai Liao, Mark Munson, Zhongli Gao, Gregory Hurlbut, Hans Peter Nestler, Ingrid Mechin, Martin Smrcina, Ronghua Li, Ryan Hartung, William Bock, Bertrand Vivet, Andrew Scholte
  • 6-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING DISEASES AND CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY
    Publication number: 20230137585
    Abstract: The invention relates to heteroaryl compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.
    Type: Application
    Filed: May 11, 2022
    Publication date: May 4, 2023
    Inventors: Zhongli Gao, Gregory Hurlbut, Mark Munson, Junkai Liao